WiLAN Subsidiary Acquires Medical Patent Portfolio OTTAWA, CANADA -- (Marketwired) -- 06/10/14 -- Wi-LAN Inc. ("WiLAN" or the "Company") (TSX: WIN)(NASDAQ: WILN) today announced that a subsidiary has acquired a portfolio of medical patents that relate to Stent technology. "With the acquisition of this medical technology, and a strong opportunity pipeline, WiLAN is seeing significant demand from inventors and small companies, in diverse markets, looking to monetize their valuable inventions," said Jim Skippen, President & CEO. "The acquired technology helps address vascular blood flow complications." The acquisition of this portfolio will be funded through an upfront payment and the sharing of net revenues generated by licensing the patents. WiLAN can confirm that it does not consider the upfront payment amount to be material relative to its current cash position. All other terms of the agreement are confidential. About WiLAN WiLAN, founded in 1992, is a leading technology innovation and licensing company. WiLAN has licensed its intellectual property to over 280 companies worldwide. Inventions in our portfolio have been licensed by companies that manufacture or sell a wide range of communication and consumer electronics products including 3G and 4G handsets, Wi-Fi-enabled laptops, Wi-Fi and broadband routers, xDSL infrastructure equipment, cellular base stations and digital TV receivers. For more information: www.wilan.com. Forward-looking Information This news release contains forward-looking statements and forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other United States and Canadian securities laws. The phrases "will be", "generated by" and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements and forward-looking information are based on estimates and assumptions made by WiLAN in light of its experience and its perception of historical trends, current conditions, expected future developments and the expected effects of new business strategies and expected future developments, as well as other factors that WiLAN believes are appropriate in the circumstances. Many factors could cause WiLAN's actual performance or achievements to differ materially from those expressed or implied by the forward-looking statements or forward-looking information. Such factors include, without limitation, the risks described in WiLAN's February 3, 2014 annual information form for the year ended December 31, 2013 (the "AIF"). Copies of the AIF may be obtained at www.sedar.com or www.sec.gov. WiLAN recommends that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of WiLAN's forward-looking statements. WiLAN has no intention and undertakes no obligation to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by law. All trademarks and brands mentioned in this release are the property of their respective owners. Contacts: For media and investor inquiries, Tyler Burns Director, Investor Relations O: 613.688.4330 C: 613.697.0367 E: email@example.com
WiLAN Subsidiary Acquires Medical Patent Portfolio
Press spacebar to pause and continue. Press esc to stop.